G protein-coupled receptors

Linnaeus Therapeutics Announces Issuance of Composition of Matter Patent for LNS8801 by the U.S. Patent and Trademark Office

Retrieved on: 
Wednesday, March 3, 2021
G protein-coupled receptors, GPER

"We are extremely pleased that the USPTO has issued this first patent under its expedited review format," commented Patrick Mooney, MD, CEO of Linnaeus.

Key Points: 
  • "We are extremely pleased that the USPTO has issued this first patent under its expedited review format," commented Patrick Mooney, MD, CEO of Linnaeus.
  • "We believe that the issued claims will provide critical market protection for LNS8801 through at least 2038.
  • LNS8801 is an orally bioavailable and highly specific and potent agonist of GPER whose activity is dependent on the expression of GPER.
  • Linnaeus Therapeutics, Inc. is a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapeutics that target G protein-coupled receptors.

GenSight Biologics Announces the Publication in Communications Biology of the Proof-of-Concept for GS030-Drug Product in Non‑Human Primates

Retrieved on: 
Thursday, February 4, 2021
Biotechnology, Pharmaceutical, Optical, Health, Branches of biology, Biology, G protein-coupled receptors, Neuroprosthetics, Opsin, Vision, Neurological disorders, Optogenetics, Photophobia, GenSight Biologics, GS030, Optogenetics, Retinitis Pigmentosa (RP)

Optogenetics combine the cellular expression of light-sensitive opsins with fine-tuned light stimulation generated by a wearable optronic visual stimulation device (GS030-MD).

Key Points: 
  • Optogenetics combine the cellular expression of light-sensitive opsins with fine-tuned light stimulation generated by a wearable optronic visual stimulation device (GS030-MD).
  • This preclinical study represents an important milestone towards the clinical validation of this approach to restore some vision in blinding retinal conditions.
  • We expect that the results of the clinical trial PIONEER will indeed confirm the potency of the approach in the interest of patients.
  • Under ambient lighting, no photophobia or visionrelated changes in behavior was noted in any of the animals injected with rAAV2.7m8-ChrimsonR-tdT.

Nanoscope® team conferred Phase II Retinal Organoid Challenge (ROC) award by National Institute of Health

Retrieved on: 
Tuesday, February 2, 2021
Branches of biology, Biology, Vision, Emerging technologies, G protein-coupled receptors, Stem cells, Neuroprosthetics, Organoid, Stargardt disease, Optogenetics, Opsin, Retina

BEDFORD,Texas, Feb. 2, 2021 /PRNewswire/ --To meet the advance challenge for generating a physiologically relevant three-dimensional (3D) retinal organoid, Nanoscope researchers in collaboration withUniversity of Colorado, and Miami Universitywere recently awarded the top prize from the 3D-ROC challenge by the National Institute of Health (NIH).

Key Points: 
  • BEDFORD,Texas, Feb. 2, 2021 /PRNewswire/ --To meet the advance challenge for generating a physiologically relevant three-dimensional (3D) retinal organoid, Nanoscope researchers in collaboration withUniversity of Colorado, and Miami Universitywere recently awarded the top prize from the 3D-ROC challenge by the National Institute of Health (NIH).
  • https://www.nei.nih.gov/about/goals-and-accomplishments/nei-research-ini...
    The organoids provide a unique opportunity for evaluating novel gene therapies including Multi-Characteristic Opsin (MCO) gene therapy for vision restoration.
  • This is an active therapeutic development area for Nanoscope Therapeutics to evaluate effectiveness of MCO optogenetic therapy, which has shown promise in restoring sight in blind subjects.
  • Our pipeline includes optogenetics based retinal regeneration therapy for vision restoration in patients with RP, Stargardt disease, and dry-AMD.

PerkinElmer Launches Industry-First GPCR TR-FRET Binding Assay and Beta-Arrestin Kits to Help Advance Therapeutics Discovery

Retrieved on: 
Tuesday, January 26, 2021
Research, Technology, Medical devices, Genetics, Software, Biotechnology, Pharmaceutical, Health, Data management, Science, Branches of biology, Cell biology, Biology, Signal transduction, G protein-coupled receptors, Cell signaling, G protein, Research, Technology, Medical devices, Genetics, Software, Biotechnology, Pharmaceutical, Health, Data management, Science, Branches of biology, Cell biology, Biology, Signal transduction, G protein-coupled receptors, Cell signaling, G protein

PerkinElmer , a global leader committed to innovating for a healthier world, today announced the addition of new assay kits to help further GPCR (G Protein-Coupled Receptor) therapeutic discovery .

Key Points: 
  • PerkinElmer , a global leader committed to innovating for a healthier world, today announced the addition of new assay kits to help further GPCR (G Protein-Coupled Receptor) therapeutic discovery .
  • These assays will help scientists continue to better understand the important role GPCRs play in disease by studying the interaction, expression and potential modulation of intracellular proteins involved in GPCR signaling mechanisms.
  • For more information on the new kits and PerkinElmers extensive line up of GPCR offerings please visit: https://www.perkinelmer.com/category/gpcr-research-reagents and https://horizondiscovery.com/en/screening/screening-libraries .
  • We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise.

RadioMedix & Curium Announce Permanent HCPCS Code for DetectnetTM (copper Cu 64 dotatate injection)

Retrieved on: 
Tuesday, January 26, 2021
Orphan drugs, Radiopharmaceuticals, Branches of biology, Drugs, Medicine, G protein-coupled receptors, Chelating agents, Macrocycles, DOTA-TATE, Somatostatin receptor 2, Copper (64Cu) oxodotreotide, Somatostatin

Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure.

Key Points: 
  • Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure.
  • The uptake of copper Cu 64 dotatate reflects the level of somatostatin receptor density in NETs, however, uptake can also be seen in a variety of other tumors that also express somatostatin receptors.
  • A negative scan after the administration of Detectnet in patients who do not have a history of NET disease does not rule out disease.
  • Non-radioactive somatostatin analogs and copper Cu 64 dotatate competitively bind to somatostatin receptors (SSTR2).

Lexicon Pharmaceuticals Enters Data Collaboration With AC Bioscience

Retrieved on: 
Wednesday, December 16, 2020
G protein-coupled receptors, Lipids, Sphingosine-1-phosphate, S1P, Lexicon Pharmaceuticals, Biology

THE WOODLANDS, Texas, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that it has entered a collaboration enabling the use by AC Bioscience LTD of preclinical and clinical data for LX2931 without granting any right or license under any of Lexicons patent rights for the compound.

Key Points: 
  • THE WOODLANDS, Texas, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that it has entered a collaboration enabling the use by AC Bioscience LTD of preclinical and clinical data for LX2931 without granting any right or license under any of Lexicons patent rights for the compound.
  • LX2931 is a small molecule sphingosine-1-phosphate (S1P) lyase inhibitor that is currently not in active development at Lexicon.
  • We are pleased to collaborate with AC Bioscience to accelerate their efforts around S1P and look forward to learning additional information about this potentially interesting pathway.
  • Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Trevena, Inc. Announces Presentations Highlighting Novel S1P1 Receptor Modulator at the American College of Neuropsychopharmacology 59th Annual Meeting

Retrieved on: 
Thursday, December 10, 2020
G protein-coupled receptors, Branches of biology, Sphingosine-1-phosphate, Opioid, S1P, Neuropathic pain

These are compelling nonclinical findings for TRV045 and support its potential application in the treatment of epilepsy and neuropathic pain.

Key Points: 
  • These are compelling nonclinical findings for TRV045 and support its potential application in the treatment of epilepsy and neuropathic pain.
  • Trevena is currently developing a novel sphingosine-1-phosphate (S1P) receptor modulator, TRV045, as a non-opioid treatment for various CNS disorders.
  • Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders.
  • The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to treating a variety of CNS disorders.

RadioMedix & Curium Announce CMS Transitional Pass-Through Status for Detectnet™ (copper Cu 64 dotatate injection)

Retrieved on: 
Wednesday, December 9, 2020
Branches of biology, Radiopharmaceuticals, Chemistry, Physical sciences, Chelating agents, Macrocycles, Neuroendocrinology, G protein-coupled receptors, DOTA-TATE, Copper (64Cu) oxodotreotide, Somatostatin receptor 2, Neuroendocrine tumor

The response to Detectnet in the neuroendocrine community has been tremendous, said Curium CEO, North America, Dan Brague.

Key Points: 
  • The response to Detectnet in the neuroendocrine community has been tremendous, said Curium CEO, North America, Dan Brague.
  • The recent inclusion in a major Appropriate Use Criteria confirms the clinical utility of Detectnet in the neuroendocrine community, said Ebrahim Delpassand, MD, CEO of RadioMedix.
  • Detectnet is indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients.
  • Non-radioactive somatostatin analogs and copper Cu 64 dotatate competitively bind to somatostatin receptors (SSTR2).

Surrozen to Present at the Stifel 2020 Virtual Healthcare Conference

Retrieved on: 
Thursday, November 12, 2020
Branches of biology, Biology, G protein-coupled receptors, Cell biology, Frizzled, Wnt signaling pathway, LRP5, Retinoic acid-inducible orphan G protein-coupled receptor, Cell signaling, Signal transduction

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced that Craig Parker, president and chief executive officer of Surrozen, will be presenting at the Stifel 2020 Virtual Healthcare Conference.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced that Craig Parker, president and chief executive officer of Surrozen, will be presenting at the Stifel 2020 Virtual Healthcare Conference.
  • The presentation will begin at 10:40 a.m. Eastern on Monday November 16th, 2020.
  • Modulation of Wnt signaling pathways has potential for treatment of degenerative diseases and tissue injuries.
  • There are 19 Wnt ligands (Wnts) in mammals, and they signal through Frizzled receptors 1-10 and co-receptors LRP5 or 6, two families of receptors.

Medikine to Present Breakthrough Discoveries of Peptide-Based Agonists of IL-7 and IL-2/15 Receptors at SITC 2020

Retrieved on: 
Tuesday, November 10, 2020
Branches of biology, Biology, G protein-coupled receptors, Pharmacodynamics, Agonist, Medical terminology, Medicinal chemistry, Physiology, Receptor

A potent and selective agonist of a form of the IL-2/15 receptor that is composed of the IL-2/15Rb and gc receptor subunits.

Key Points: 
  • A potent and selective agonist of a form of the IL-2/15 receptor that is composed of the IL-2/15Rb and gc receptor subunits.
  • A bispecific recombinant Fc fusion protein incorporating both IL-7R and IL-2/15Rbgc agonist peptides that demonstrates agonist activity on both receptors.
  • This work builds on previous discoveries of peptide agonists for the homodimeric receptors for erythropoietin and thrombopoietin by members of the Medikine team," said Ronald W. Barrett, Ph.D., CEO and chairman of Medikine.
  • "We are pleased to present these innovations at SITC and are now moving the IL-7R and IL-2/15Rbgcagonist programs into development.